242 related articles for article (PubMed ID: 34207648)
1. Oligometastatic Breast Cancer: How to Manage It?
Barberi V; Pietragalla A; Franceschini G; Marazzi F; Paris I; Cognetti F; Masetti R; Scambia G; Fabi A
J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207648
[TBL] [Abstract][Full Text] [Related]
2. Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.
Merloni F; Palleschi M; Casadei C; Romeo A; Curcio A; Casadei R; Stella F; Ercolani G; Gianni C; Sirico M; Cima S; Sarti S; Cecconetto L; Di Menna G; De Giorgi U
Ther Adv Med Oncol; 2023; 15():17588359231161412. PubMed ID: 36950272
[TBL] [Abstract][Full Text] [Related]
3. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Kobayashi T; Ichiba T; Sakuyama T; Arakawa Y; Nagasaki E; Aiba K; Nogi H; Kawase K; Takeyama H; Toriumi Y; Uchida K; Kobayashi M; Kanehira C; Suzuki M; Ando N; Natori K; Kuraishi Y
Breast Cancer; 2012 Jul; 19(3):218-37. PubMed ID: 22532161
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report.
Nagasaki E; Kudo R; Tamura M; Hayashi K; Uwagawa T; Kijima Y; Nogi H; Takeyama H; Suzuki M; Nishikawa M; Yano S; Kobayashi T
Breast Cancer; 2021 Sep; 28(5):1051-1061. PubMed ID: 33840010
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with oligometastatic breast cancer - A systematic review.
van Ommen-Nijhof A; Steenbruggen TG; Schats W; Wiersma T; Horlings HM; Mann R; Koppert L; van Werkhoven E; Sonke GS; Jager A
Cancer Treat Rev; 2020 Dec; 91():102114. PubMed ID: 33161237
[TBL] [Abstract][Full Text] [Related]
6. Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.
Kent CL; McDuff SGR; Salama JK
Ann Palliat Med; 2021 May; 10(5):5954-5968. PubMed ID: 32921069
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Steenbruggen TG; Schaapveld M; Horlings HM; Sanders J; Hogewoning SJ; Lips EH; Vrancken Peeters MT; Kok NF; Wiersma T; Esserman L; van 't Veer LJ; Linn SC; Siesling S; Sonke GS
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 33977227
[TBL] [Abstract][Full Text] [Related]
8. SABR in oligometastatic breast cancer: Current status and future directions.
Stewart R; White M; Tan J; Siva S; Karroum L; David S
Breast; 2021 Dec; 60():223-229. PubMed ID: 34739890
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?
Di Lascio S; Pagani O
Breast Care (Basel); 2014 Feb; 9(1):7-14. PubMed ID: 24803881
[TBL] [Abstract][Full Text] [Related]
10. Treatment Strategies for Oligometastatic Breast Cancer.
Nesbit EG; Donnelly ED; Strauss JB
Curr Treat Options Oncol; 2021 Aug; 22(10):94. PubMed ID: 34426881
[TBL] [Abstract][Full Text] [Related]
11. Survival and prognostic factors in oligometastatic breast cancer.
van Ommen-Nijhof A; Steenbruggen TG; Capel L; Vergouwen M; Vrancken Peeters MT; Wiersma TG; Sonke GS
Breast; 2023 Feb; 67():14-20. PubMed ID: 36549169
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.
Steenbruggen TG; Wolf DM; Thijssen B; Sanders J; Cornelissen S; Salgado R; Mittempergher L; Bhaskaran R; Broeks A; Lips EH; Siesling S; Sonke GS; Horlings HM; van 't Veer LJ
JCO Precis Oncol; 2023 Sep; 7():e2200670. PubMed ID: 37738542
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. Role of radiotherapy in oligometastatic breast cancer: Review of the literature.
Beduk Esen CS; Gultekin M; Yildiz F
World J Clin Oncol; 2022 Jan; 13(1):39-48. PubMed ID: 35116231
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic breast cancer.
Kwapisz D
Breast Cancer; 2019 Mar; 26(2):138-146. PubMed ID: 30324552
[TBL] [Abstract][Full Text] [Related]
17. Defining Oligometastatic Bladder Cancer: A Systematic Review.
Bamias A; Stenzl A; Zagouri F; Andrikopoulou A; Hoskin P
Eur Urol Open Sci; 2023 Sep; 55():28-37. PubMed ID: 37662704
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer under age 40: a different approach.
Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
[TBL] [Abstract][Full Text] [Related]
20. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
